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In this study we test the hypothesis that endogenous particles in exhaled air (PEx), non-
invasively sampled from lower airways, are well suited for the analysis of respiratory tract
lining fluid (RTLF) proteins, i.e., surfactant protein A (SP-A) and albumin.
Ten healthy volunteers were included in the study and participated in two sampling sessions.
Blood, exhaled breath condensate (EBC) and PEx were collected at each session. 100 L of breath
were collected for each exhaled sample. Serumandexhaled sampleswere analyzed for SP-A using
an in-house ELISA. Albumin was analyzed in exhaled samples using a commercial ELISA kit.
SP-A detection rates were 100%, 21%, and 89% for PEx, EBC and serum, respectively. Albumin
was detected in PEx, but not in EBC. SP-A measurements in PEx showed good repeatability with
an intra-individual coefficient of variation of 13%. Both SP-A andalbumin showed significant corre-
lation to mass of PEx (rsZ 0.93, p < 0.001 and rsZ 0.86, pZ 0.003, respectively).
Sampling and analysis of PEx is a valid non-invasive method to monitor RTLF proteins sampled
from the lower respiratory tract, as demonstrated here by example of SP-A and albumin analysis.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Adult humans inhale about 10,000 L of air daily, exposing
our respiratory system to air pollutants and pathogens that
are potentially hazardous to health. In spite of the relative
accessibility of the respiratory system in comparison tomm.gu.se (A.-C. Olin).
1 Elsevier Ltd. All rights reservedother organs, direct assessment of health effects from
environmental and occupational exposures is challenging.
At present, there are very few methods available for
monitoring respiratory diseases affecting distal airways,
e.g., chronic obstructive pulmonary disease (COPD) or
interstitial lung disease. Standard procedures for collecting.
Table 1 Study population.
m/fa Age (years)
Median (range)
BMI
Median (range)
FEV1% predictedb
Median (range)
5/4 31 (28, 57) 24 (21, 27) 109 (90, 122)
a m/f number of males and females.
b FEV1% is percent of predicted forced expiratory volume in
1 s.
198 P. Larsson et al.samples from the respiratory tract are either invasive, such
as bronchoalveolar lavage (BAL), or associated with meth-
odological difficulties such as sputum induction and exhaled
breath condensate (EBC). At present, EBC analysis is the
only commercially-available non-invasive method for col-
lecting samples from the respiratory tract. However, non-
volatile compounds found in EBC samples typically have
concentrations below or near the detection limit of
currently available assays.1
We have recently developed a method for collecting
non-volatile material from exhaled air.2 The method is non-
invasive and is based on the collection of endogenous
Particles in Exhaled air (PEx). The majority of the sampled
particles are likely to be formed during the opening of the
distal airway and to follow the airstream during subsequent
exhalation.3 Sampling of PEx includes simultaneous count-
ing of number of exhaled particles in different size-ranges,
which is advantageous in quantitative analysis.
The study described in this paper tests the hypothesis that
sampling particulatematerial in exhaled air is a reproducible
method for collecting the respiratory tract lining fluid from
the distal airways and can be used to quantify surfactant
protein A (SP-A) and albumin levels. SP-A and albumin, two
proteins known tobeabundant in respiratory tract liningfluid
(RTLF) from the distal airways, were selected to evaluate
correlation between detected protein amounts and themass
of collected PEx. SP-A is the major surfactant protein and is
produced locally by alveolar type II cells.4 SP-A is important
for both host defense mechanisms and surfactant function,5
and is considered to be a potential biomarker for airway
inflammation for respiratory diseases, such as asthma,6,7
COPD,8 idiopathic pulmonary fibrosis9 and bronchiolitis
obliterans syndrome.10 Albumin is the major blood protein
and is abundant in RTLF because of the leakage of plasma
protein into the airways.11
Material and methods
Study population
Ten healthy volunteers from Gothenburg, Sweden, partici-
pated in the study; five women and five men. One subject did
notperformthebreathingmaneuver correctly; thereforedata
obtained from this subjectwere excluded from the study. The
results from the remaining nine subjects are presented. All
participants were non-smokers, and underwent a spirometry
test (Spirare 3 sps 310, software version 3.35.11, Oslo, Nor-
way) in accordance with ERS guidelines.12 On the basis of the
spirometry tests and their responses to questionnaires, all of
the participants were judged to be in good health. Table 1
provides additional information on the subjects.
Study design
Each subject participated in two sampling sessions over the
course of one week. In each of these sessions, three types of
samples were acquired: EBC, PEx and serum. The sampling
sessions took place between 09:00 and 12:00 AM to reduce
the influence of diurnal variation. The EBC sample was
collected first, followed by sampling of PEx; the same
quantity of exhaled air was sampled in both cases. EBC wassampled using tidal breathing, while subjects were reques-
ted to perform a predefined breathing maneuver (described
in details later in this paper) during the acquisition of PEx
samples. The breathing maneuver was chosen on the basis of
the results obtained from our previous study on PEx forma-
tion.3 To examine the influence of the breathing pattern on
thecontents of theEBC, a second sampleof EBCwasobtained
from three of the subjects using the breathing maneuver
employed in PEx sampling.
Serum
Blood was drawn into serum gel tubes (Vacuette SST,
greiner bio-one GmbH, Kremsmu¨nster, Austria), allowed to
clot for 45 min and centrifuged at 1320  g for 10 min at
room temperature. The serum was transferred to 2 ml
Protein LoBind Tubes (Eppendorf, Hamburg, Germany) and
stored at 20 C prior to analysis.
PEx
PEx were collected with an instrument developed in-house
as described previously.2 The instrument was modified to
control the flow path of the exhaled air, enabling us to
sample exclusively exhalations performed with a specific
breathing maneuver. Subjects rinsed their mouth with
distilled water and breathed filtered air for 2 min before
the sampling started. All subjects wore a nose clip
throughout the entire procedure. The test subjects were
instructed to perform the following three-step breathing
maneuver during sampling:
i. Exhale fully until only the residual volume remains in
the lungs and hold their breath for a few seconds.
ii. Inhale rapidly until the lungs are filled to their vital
capacity.
iii. Exhale back to residual volume at a peak flow of
1000e1500 mL s1. The exhalation flow was shown to
the test subject on a computer screen.
Only iii, the last exhalationwas sampled in the instrument.
The numbers of particles were monitored using an online
particle counter. The number of PEx is defined as the sum of
particles with an aerodynamic diameter of
d Z S0.414.55 mm that are sampled by the impactor.13
Between breathing maneuvers, the test subject breathed
particle-free air tidally. The procedurewas repeated until the
total volume sampled was 100 L. The sample was extracted
from the silicon plate by ultrasonication for 5 min in 115 mL of
a desorption solvent consisting of 0.01 M PBS at pH 7.4 (Medi-
cago AB, Uppsala, Sweden) containing 0.13% Tween-20 (Bio-
Surfactant protein A and albumin 199Rad, Hercules, CA, USA) and diluted with 200 mL water. The
solutionwas then transferred to2mLProtein LoBindTubes and
dried thoroughly by evaporation under reduced pressure.
Samples were stored dry at 20 C prior to analysis. For the
analysis, the dry samples were reconstituted by adding 115 mL
MilliQ-water.
Exhaled breath condensate
EBC was collected using an ECoScreen instrument (Jaeger,
Wu¨rzburg, Germany) and the exhaled volume was measured
with an EcoVent flow meter (Jaeger, Wu¨rzburg, Germany).
The flow meter was calibrated with a 3 L calibration syringe
from New Diagnostic Designs (Zu¨rich, Switzerland) at the
start of the study and the calibration was verified at the end
of the study. Subjects rinsed their mouth with distilled water
before sampling and then breathed tidally while wearing
a nose clip, until the total exhaled volume reached 100 L. The
lamellar tube was allowed to reach room temperature and
then centrifuged for 5 min at 200  g to ensure that the
samplewas located in theobtainer at the bottomof the tube.
The EBC sample was then transferred from the obtainer to
2 ml Protein LoBind Tubes and stored at 20 C. Prior to
analysis, EBC samples were dried thoroughly by evaporation
under reduced pressure and then reconstituted in 115 ml of
a solution of 0.01 M PBS at pH 7.4 containing 0.13% Tween-20.
Albumin ELISA
Albumin was determined with a commercial E-80AL ELISA
kit (Immunology Consultant Laboratory, Newberg, OR, USA)
using the protocol suggested by the manufacturer. 10 mL of
sample was used and all samples were analyzed using the
same ELISA plate. Plate absorbance was read at 450 nm by
BioTek ELx-808UI (Highland Park, MI, USA). The concen-
tration of albumin in the samples was calculated from
a four parametric standard curve using BioTek software KC
Junior V1.41.8 (Highland Park, MI, USA).
SP-A ELISA
SP-A was measured using a sandwich ELISA as described by
Ellingsen et al.14 The primary antibody was AB3422 (Milli-
pore, Billerica, MA, USA); the secondary antibody was HYB
238-04 (Antibody Shop, Gentofte, Denmark). 100 mL of
sample was used in the SP-A ELISA and all samples including
a negative control sample were analyzed on the same ELISA
plate. As a reference and standard for a calibration curve,
aliquots from pooled serum samples with a known high
response. No pure reference protein standard of known
amount was available therefore SP-A amount is reported in
arbitrary units (au).
Validation
The coefficient of variation (CV) for the albumin assay was
below 5% as calculated from a single PEx sample, split into
four equal parts prior to analysis. The limit of detection (LoD)
was estimated to be 3.0 ng mL1 for albumin on the basis of
the lowest standard reported by the ELISA software
(recovery 74%, CV 7%).To validate the inter- and intra-assay CV of the SP-A
assay, a pooled PEx sample of 1000 L exhaled breath ob-
tained from six test subjects was split into eight aliquots
and analyzed in quadruplicate on two ELISA plates. The
observed intra-assay CV was 3%; the inter-assay CV was
25%. Different batches of antibodies were used in the first
and second assays.
A negative control was included in every ELISA run. The
only difference between the negative control and a sample
was that no exhaled breath was sampled when the control
was placed in the PEx instrument in all other ways it was
treated as a sample. The negative control was placed in the
PEx instrument for 30 min as this is approximately the
sampling time required. The negative control was below
detection limit in both the SP-A and albumin assay.
The loss of material during the extraction procedure was
tested using two serum samples with known SP-A concen-
trations. Samples were spotted onto silicon plates as ten
spots of 1 mL each and left to dry for 1 h at room temper-
ature. The sample spots were then frozen for an hour at
20 C before being extracted and analyzed according to
the protocol described previously. The mean recovery for
the two samples was 93% (range 4.6e4.7 au).
To evaluate the PExmatrix and possible interference from
lipids, serum samples were mixed with Curosurf (Nycomed
GmbH, Zurich, Switzerland), a commercially available pig
surfactant. Two concentrations of Curosurf were tested (8.0
and 0.8 mg mL1). The Curosurf/serum mixture was spotted
onto a siliconplate (10 spots of 1mL, per plate), allowed todry
and then extracted as described previously. Duplicates of
three concentrations of Curosurf (0, 0.8, 8.0 mg mL1) were
analyzed and the coefficient of variation was found to be 8%
(mean amount 12.7e10.9e12.2 au respectively). In addition
a standard addition test was performed to evaluate matrix
effect. A pooled sample obtained from 900 L of exhaled air
was extracted and split into five equivalent samples. To these
five aliquots, standardwas added in increasing concentration
to construct a standard curve. The average increase in each
spiked sample compared to standard without sample was 0,9
and the slope of the standard curve without sample was not
significantly different to that with sample (linear regression
0.208 and 0.208).
To evaluate the storage stability of SP-A 200 L of exhaled
breath was sampled as previously described. Half of the
sample, seen as five spots on the silicon surface (out of ten
spots), was extracted from the plates with extraction
solvent (0.01 M PBS/0.13% Tween-20) by pipetting and the
extract was analyzed on the same day. The other half was
stored for eight months at 20 C prior to analysis. The
storage test was performed twice to get a more reliable
result. The recovery after storage was 86% and 93%. The
LoD was estimated to be 0.2 au for SP-A (relative error
<50% with 95% CI).Statistics
If the concentration of a given analyte in a sample was
below the limit of detection, it was assigned to be equal to
LoD/O2.15 When calculating intra-individual coefficient of
variation (CV) only test subjects that had two samples
above LoD were included. The overall intra-individual
200 P. Larsson et al.variation was calculated as the mean of the CV for each of
the subjects. The inter-individual CV was calculated from
the mean concentration for each subject. CV values, means
and standard errors were calculated using Microsoft Excel
2007. SAS v9.2 (Raleigh-Durham, NC, USA) was used to
calculate Spearman correlation coefficients and quartiles.
The significance level was set to p < 0.05.Ethics
All participants gave their written informed consent. The
study protocol was approved by the Regional Ethical Review
Board in Gothenburg.Results
SP-A
SP-A amounts from the nine subjects are presented in Table
2. SP-A was detected in all PEx samples, in four EBC
samples and in 16 serum samples. There was no significant
correlation between PEx-SP-A and serum-SP-A. The intra-
individual CV for PEx was 13% and the inter-individual CV
was 25%. In serum, the intra-individual CV was 7% and the
inter-individual CV was 127%. The relationship between
individual means for estimated mass of sampled particles
and SP-A is shown in Fig. 1.Albumin
Albumin amounts are presented in Table 3. Albumin was
detected in 14 PEx samples and (at a low amount) in one
EBC sample. For albumin in PEx samples, the intra-
individual CV was 50% and the inter-individual CV was
104%. The relationship between individual means for esti-
mated mass of sampled particles and albumin is shown in
Fig. 2.Table 2 Amount of sampled surfactant protein A in arbitrary u
Subject PEx-SP-A (au) EB
Session 1 Session 2 Ses
1 1.4 1.5 <L
2 4.0 3.3 <L
3 3.5 2.7 <L
4 3.4 2.8 <L
5 2.2 1.9 1.6
6 2.5 3.0 0.5
7 2.1 2.8 <L
8 2.2 3.0 <L
9 2.4 2.2 <L
Median (Q1eQ3) 2.6 (2.2e3.0) e
PEx-SP-A: The amount of surfactant protein A in sample collected fro
air.
EBC-SP-A: The amount of surfactant protein A in sample collected fro
Serum-SP-A: The amount of surfactant protein A in 100 mL of serum sPEx
Total mass of sampled material is presented in Table 3. The
total mass was calculated based on the number and the size
of the collected particles. The particles were assumed to
be spherical in shape and have the density of 1000 kg/m3.
PEx mass in samples had an intra-individual CV of 24% and
an inter-individual CV of 61%.
Correlation between the mass of PEx and the
protein amounts
The correlation between the amount of SP-A and themass of
PEx was highly significant (rsZ 0.93, p < 0.001). There was
also a highly significant correlation between the amount of
PEx and the amount of albumin (rs Z 0.86, p Z 0.003).
EBC sampled using the predefined breathing
maneuver
Three subjects underwent an additional sampling of their
EBC (100 L of exhaled air) using the same breathing
maneuver as was used when acquiring the PEx samples, i.e.
maneuver that induces airway closure and re-opening. In all
three samples, the concentrations of SP-A were below the
LoD. Only one subject had an albumin amount above the
LoD; the albumin amount in this case was 17.2 ng.
Discussion
SP-A was readily and repeatedly detected in PEx; the intra-
individual CV for SP-A was 13% for two sampling occasions
within one week. This stands in contrast to the situation
with EBC samples of the same exhaled volume, in which
only 4 out of 18 samples exhibited SP-A concentrations
above the LoD. Albumin could also be detected in most PEx
samples but not in EBC samples. These data indicate that
for sampling non-volatile compounds, the PEx method is
more efficient than using the EBC approach.nits (au).
C-SP-A (au) Serum-SP-A (au)
sion 1 Session 2 Session 1 Session 2
oD <LoD 72.6 78.8
oD 0.76 <LoD <LoD
oD <LoD 15.2 16.1
oD <LoD 14.1 14.8
5 <LoD 0.7 0.7
7 <LoD 18.0 17.9
oD 0.48 17.6 17.9
oD <LoD 1.3 1.6
oD <LoD 23.0 16.1
15.6 (1.3e17.9)
m 100 L using the method based on sampling particles in exhaled
m 100 L of breath using the exhaled breath condensate method.
ample.
Fig. 1 The relationship between sampled mass of particles (ng) and mass of surfactant protein A (au) in sample.
Surfactant protein A and albumin 201SP-A and albumin concentrations in PEx were strongly
correlated with the mass of PEx. This observation is in
agreement with our hypothesis that non-volatile
compounds in exhaled air can be transported as aerosol
particles. The extent to which these aerosolized particles
are formed and exhaled is highly dependent on the nature
of the subject’s breathing.2,3,16 The breathing maneuver
described above, in which the bulk of the PEx are formed by
the closure and re-opening of the airways,3 provides control
over the sample origin. Using this breathing maneuver,
RTLF from the terminal bronchioles is the most likely source
of the SP-A in PEx collected from healthy subjects.
One of our hypotheses was that the mass of particles in
PEx samples should reflect the amount of the collected
RTLF. The results demonstrated that this hypothesis is valid
for both SP-A and albumin.Table 3 Albumin amount in PEx and EBC and the total mass in
Subj PEx-Albumin
(ng)
EBC
(ng
Session 1 Session 2 Ses
1 <LoD <LoD 0.3
2 9.60 17.21 <L
3 7.21 9.60 <L
4 12.82 17.26 <L
5 4.42 2.50 <L
6 0.53 9.36 <L
7 <LoD 1.02 <L
8 2.42 2.80 <L
9 <LoD <LoD <L
Median (Q1eQ3) 2.65 (0.21e9.60) e
PEx-SP-A: The amount of albumin in sample collected from 100 L air
EBC-SP-A: The amount of albumin in sample collected from 100 L of
PEx is the total mass of sample estimated from total number of partiComparison to existing methods
Like the EBC approach, the PEx method involves sampling
of material from exhaled air. However, unlike EBC instru-
ments that use cooling to condense water vapor and in
doing so, possibly catching some droplets from the aerosol,
the PEx instrument uses a cascade impactor developed for
sampling particles. The amount of non-volatile material in
exhaled breath may vary significantly among individuals
and there is no reason to believe that particle formation is
kept constant or is related in a constant fashion to the
production of water vapor.17 The number of exhaled
particles is not monitored in the EBC method, and
measured aqueous concentrations cannot be adjusted
according to the amount of sampled material. EBC
instruments are designed for sampling during tidalsample.
-Albumin
)
ng of PEx
(d Z S0.414.55 mm)
sion 1 Session 2 Session 1 Session 2
1 <LoD 51 54
oD <LoD 315 395
oD <LoD 312 239
oD <LoD 251 310
oD <LoD 99 123
oD <LoD 160 432
oD <LoD 72 160
oD <LoD 127 181
oD <LoD 107 95
160.4 (98.5e310.0)
using the method based on sampling particles in exhaled air.
air using the exhaled breath condensate method.
cles sampled in the diameter interval d Z S0.41  4.55 mm.
Fig. 2 The relationship between sampled mass of particles (ng) and mass of albumin (ng) in sample.
202 P. Larsson et al.breathing and tidal breathing produces only a small
amount of particulate material compared to the breathing
technique used in the PEx method.3 Condensation in
general is not an efficient way to sample particles. The
non-volatile material found in ECB is most likely collected
by impaction or gravitational settling of aerosol particles
in the apparatus. These processes are aided by the growth
of the particles due to condensation on cooling. Another
possibility is thermophoretic transport toward the walls of
the cooler if the thermal gradient is large. This implies
that the ECB collection causes size discrimination of the
collected material and might explain why particles that
contain SP-A and albumin18 are not efficiently transferred
to the EBC sample, and why no improvement was observed
when the PEx breathing maneuver was applied in EBC
sampling.
It is likely that, PEx are sampled from the distal airways.
Therefore, PEx could potentially serve as a non-invasive
alternative to BAL for monitoring inflammation in the distal
part of the lung. In contrast to BAL sampling, PEx is simple,
does not require special medical training on the part of the
practitioner or sedation of the subject and is suitable for
repeated sampling. Therefore the PEx method has advan-
tages that could make it useful for monitoring the devel-
opment of respiratory diseases and the progress of their
treatment in larger populations. Sputum induction is a less
invasive method for sampling RTLF than is BAL, but it is
more cumbersome and primarily samples material from the
central airways.19 A key advantage of the PEx method
relative to both BAL and sputum induction is that it does not
disrupt the RTLF by introducing foreign substances that can
induce changes in the RTLF composition or dilute the
sample in an unpredictable manner. The limitation of the
PEx method compared to BAL and sputum is that no cells
are sampled and only low amounts of extracellular material
are collected.
We did not observe any correlation between the levels
of SP-A in serum and those in PEx, indicating that serumSP-A is not a relevant measure of the concentrations of
these proteins in RTLF. The concentrations of SP-A in the
serum of the subjects (all of whom were in good health) of
this study varied over a wide range (100-fold) between
different subjects, but the intra-individual variation was
low (7%). This high variability between individuals has
been described in a previous study using the same anti-
body.14 In healthy individuals it seems unlikely that these
differences reflect differences in the alveolo-capillary
barrier.Limitations of the study
The exhalations sampled in the PEx method contain very
small amounts of particulate material (approximately
50e400 ng based on particle data). To maximize recovery,
the solvent volumes used in processing and extracting the
samples were kept to a minimum and the samples were
concentrated by vacuum evaporation. Vacuum evaporation
could potentially alter the protein structure and the ELISA
results. However, we observed good recovery during the
validation experiments, suggesting that this is unlikely to
be a problem in this study.
In this study we used a predefined breathing maneuver
to ensure that the particles exhaled by each individual
subject were formed by the same mechanism. Even though
there are strong indications that airway opening in the
distal airways is the major source of particles when this
breathing maneuver is used, the possibility of confounding
sources, such as dynamic compression in more central
airways still exists. However, no amylase contamination
was detected in PEx samples pooled from several thousand
liters of exhaled breath using liquid chromatography-mass
spectrometry.20
SP-A analyses were limited by the lack of a pure
standard, especially since the standard matrix was
different from the PEx matrix. All the samples were
Surfactant protein A and albumin 203treated in the same way; therefore, it was possible to
assess their relative SP-A concentrations. We did not test
for cross reactivity in the SP-A ELISA, this has previously
been done by Madsen et al4 who did not detect any
cross-reactivity using the same monoclonal antibody (HYB
238-04) in BAL samples. The PEx matrix is less complex
than the BAL matrix and since the analyzed proteins are
major components of the PEx samples20; this is likely to
further reduce the risk of interfering cross reactivity for
the PEx samples.
Clinical relevance
There is a need for better tools to diagnose and monitor
respiratory diseases such as asthma and COPD. It is well
established that respiratory symptoms only to a minor
extent reflect airway inflammation and spirometry is often
normal in the early stage disease. To be able to perform
repeated measurements and follow the progression of
disease new methods are warranted. Today we are lacking
the methods for monitoring in the RTLF, particularly in the
distal airways. Our data show that the PEx method has
potential to become a valuable tool for monitoring
inflammatory processes.Conclusions
Sampling and analysis of PEx is a valid non-invasive method
for detecting RTLF proteins, as demonstrated in this study
by measuring levels of SP-A and albumin. The mass of
exhaled particles correlate strongly with the measured
concentrations of these proteins, and the results obtained
are highly reproducible. Future research in this area will
focus on expanding the scope of the PEx method by eval-
uating it as a tool for examining patients with respiratory
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